Holen Sie sich die Stockscreener-App
123.74
2.05%
-2.59
Handel nachbörslich:
124.84
1.10
+0.89%
Schlusskurs vom Vortag:
$126.33
Offen:
$125.67
24-Stunden-Volumen:
1.96M
Relative Volume:
0.52
Marktkapitalisierung:
$27.02B
Einnahmen:
$819.56M
Nettoeinkommen (Verlust:
$-1.18B
KGV:
-21.54
EPS:
-5.7434
Netto-Cashflow:
$-951.64M
1W Leistung:
-5.61%
1M Leistung:
+12.38%
6M Leistung:
-16.81%
1J Leistung:
-3.14%
1-Tages-Spanne:
$122.21
$126.84
1-Wochen-Bereich:
$122.21
$135.50
52-Wochen-Spanne:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Firmenname
Insmed Inc
Sektor
Branche
Telefon
908-977-9900
Adresse
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
123.74 | 28.89B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Raymond James | Outperform |
| 2026-03-30 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2026-03-16 | Fortgesetzt | Jefferies | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2026-01-23 | Eingeleitet | Roth Capital | Buy |
| 2025-12-19 | Fortgesetzt | Truist | Buy |
| 2025-12-04 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-28 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2025-10-20 | Eingeleitet | Wells Fargo | Overweight |
| 2025-08-20 | Eingeleitet | William Blair | Outperform |
| 2025-08-13 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | Eingeleitet | Jefferies | Buy |
| 2025-02-25 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2024-04-23 | Eingeleitet | Truist | Buy |
| 2024-02-15 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-07-26 | Eingeleitet | Guggenheim | Buy |
| 2022-12-09 | Eingeleitet | Mizuho | Buy |
| 2022-12-07 | Eingeleitet | Barclays | Overweight |
| 2022-11-18 | Eingeleitet | BofA Securities | Buy |
| 2022-04-27 | Eingeleitet | Goldman | Buy |
| 2021-12-06 | Eingeleitet | JP Morgan | Overweight |
| 2021-10-19 | Fortgesetzt | Monness Crespi & Hardt | Buy |
| 2021-10-19 | Fortgesetzt | Morgan Stanley | Overweight |
| 2021-10-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Outperform |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-10-12 | Fortgesetzt | Stifel | Buy |
| 2019-09-03 | Eingeleitet | Goldman | Buy |
| 2019-04-09 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-15 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | Hochstufung | Goldman | Neutral → Buy |
| 2019-01-02 | Eingeleitet | Canaccord Genuity | Buy |
| 2018-08-06 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | Eingeleitet | Goldman | Neutral |
| 2018-04-23 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | Eingeleitet | Morgan Stanley | Overweight |
| 2018-01-18 | Eingeleitet | Credit Suisse | Neutral |
| 2017-09-05 | Bestätigt | Evercore ISI | Outperform |
| 2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
| 2017-07-11 | Eingeleitet | Robert W. Baird | Outperform |
| 2016-03-15 | Eingeleitet | Stifel | Buy |
| 2015-11-09 | Herabstufung | UBS | Buy → Neutral |
| 2015-10-06 | Bestätigt | H.C. Wainwright | Buy |
| 2015-06-09 | Eingeleitet | Citigroup | Neutral |
| 2014-03-26 | Bestätigt | HC Wainwright | Buy |
Alle ansehen
Insmed Inc Aktie (INSM) Neueste Nachrichten
Darwin Global updates Insmed Inc (INSM) ownership, reporting 3.0% beneficial stake - Stock Titan
Insmed (INSM) Q2 2026 Earnings Call Transcript - AOL.com
Insmed(INSM.US) Officer Sells US$31.96 Million in Common Stock - Moomoo
FY2026 Earnings Forecast for Insmed Issued By HC Wainwright - MarketBeat
Handelsbanken Fonder AB Grows Stake in Insmed, Inc. $INSM - MarketBeat
Insmed (NASDAQ:INSM) COO Sells 239,850 Shares - MarketBeat
Insmed Insider Sold Shares Worth $31,964,810, According to a Recent SEC Filing - marketscreener.com
Insmed Chief Operating Officer Sold Shares Worth Over $31M - TradingView
INSMED Inc (INSM) COO exercises 239,850 options and sells matching shares - Stock Titan
HC Wainwright Brokers Increase Earnings Estimates for Insmed - MarketBeat
Insmed to Host First-Quarter 2024 Financial Results Conference Call on Thursday, May 9, 2024 - kalkine.ca
Analysts Offer Insights on Healthcare Companies: Insmed (INSM), Minerva Neurosciences (NERV) and Zymeworks (ZYME) - The Globe and Mail
INSM (INSM) insider notice covers 239,850 shares and prior sales data - Stock Titan
INSM Maintained by JP Morgan -- Price Target Lowered to $175 - GuruFocus
Insmed (NASDAQ:INSM) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co. - MarketBeat
INSM Reiterates by Truist Securities -- Price Target Raised to $195 - GuruFocus
$1000 Invested In Insmed 5 Years Ago Would Be Worth This Much Today - Benzinga
H.C. Wainwright reiterates Buy on Insmed stock, $220 target By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Buy on Insmed stock, $220 target - Investing.com India
High Growth Tech Stocks in the US to Watch - simplywall.st
Pacer Advisors Inc. Has $1.19 Million Holdings in Insmed, Inc. $INSM - MarketBeat
Assenagon Asset Management S.A. Acquires 155,011 Shares of Insmed, Inc. $INSM - MarketBeat
Insmed Inc (INSM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Insmed (NASDAQ:INSM) Posts Earnings Results - MarketBeat
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Insmed (INSM) Stock Cools As BRINSUPRI Surge Recasts Growth Profile - simplywall.st
Insmed Insider Sold Shares Worth $3,494,838, According to a Recent SEC Filing - marketscreener.com
INSM Maintained by Guggenheim -- Price Target Lowered to $205 - GuruFocus
Insmed slips as investors digest a sharp post-earnings rally - Quiver Quantitative
INSM Maintained by Wells Fargo -- Price Target Raised to $169 - GuruFocus
Insmed Outlook Strengthens After Q2 Results, RBC Says - Yahoo Finance
What Insmed Stock’s Premium Is Actually Buying - Trefis
INSM Maintained by Evercore ISI Group -- Price Target Raised to $170 - GuruFocus
Has Insmed (INSM) Risen Above Fair Value After Its 3 Year Run? - finance.yahoo.com
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake - Zacks Investment Research
Insmed Stock: Is a Historic Drug Launch a Clear Buy Signal? - Trefis
Insmed Incorporated Q2 2026 Earnings Call Summary - finance.yahoo.com
INSM SWOT Analysis: Financial Strengths and Challenges Revealed in 10-Q Filing - GuruFocus
Quantinno Capital Management LP Grows Stock Holdings in Insmed, Inc. $INSM - MarketBeat
INSM|Insmed Inc|Price:134.620|Chg%:+3.520 - TradingKey
Insmed (INSM) Is Up 30.6% After Steeply Narrowing Losses And Raising 2026 Revenue Guidance – What’s Changed - finance.yahoo.com
Insmed (INSM) Soars 33.86% as Brinsupri Drives Fourfold Growth. Here’s What to Watch Next - finance.yahoo.com
Insmed Incorporated Stock 12‑Month Price Target Raised to $197.14, Implies 99% Upside - TradingView
Insmed Q2 Earnings Call Highlights - MarketBeat
Insmed Stock Rockets As Analysts Hike Targets On TPIP Data - StocksToTrade
INSMED INC : LEERINK PARTNERS RAISES TARGET PRICE TO $210.00 FROM $205.00 - Bitget
Insmed Catapults 34%, Leading A Biotech Rally. But Mirum Takes A Bath. - Investor's Business Daily
Reporting person for NASDAQ: INSM plans 27,173-share sale after prior trades - Stock Titan
INSMED INC : GUGGENHEIM CUTS TARGET PRICE TO $205 FROM $207 - Bitget
Insmed Inc (INSM) (Q2 2026) Earnings Call Highlights: BRINSUPRI - GuruFocus
Insmed Inc Stock (INSM) Moved Up by 31.83% on Aug 6: Key Drivers Unveiled - TradingKey
Finanzdaten der Insmed Inc-Aktie (INSM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.22%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):